A new method that prevents the loss of silencing activity of double-strand RNA in humans

Since the discovery that short double-strand RNA molecules (siRNAs) can trigger sequence-specific degradation of target RNA in cells, great efforts are going on throughout the world to use siRNAs in human therapy.

The group of Dr. Dr. Albrecht Piiper at the Saarland University discovered a way to defend double-stranded and partial double-stranded molecules of RNA – particularly siRNAs – from degradation by RNAse in mammalian body fluid including humans.

Further Information: PDF

Universität des Saarlandes Wissens- und Technologietransfer GmbH PatentVerwertungsAgentur der saarländischen Hochschulen
Phone: +49 (0)681/9386376

Contact
Dipl.-Kfm. Axel Koch MBA, Dr. Dirk Schwingel

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Visualization of selective RNA technology targeting glioblastoma cells.

Self-Destructing Cancer Cells: Cutting-Edge RNA Breakthrough

Jülich scientists use novel RNA technology to selectively switch off tumours in the brain. An Adaptable Platform Technology That Destroys Glioblastoma Cancer Cells Using a special RNA molecule, a team…

HFpEF patients engaging in endurance and strength training as part of a clinical trial on exercise therapy for heart failure.

Endurance Training: Transforming Lives of Heart Failure Patients

Can strength and endurance training be beneficial for patients with a certain form of heart failure? A research team from Greifswald investigated this question together with seven other research centers…

A map highlighting shark conservation measures in the Mediterranean Sea.

A Wake-Up Call for Mediterranean Shark Protection Against Extinction

Overfishing, illegal fishing and increasing marketing of shark meat pose significant threats to the more than 80 species of sharks and rays that inhabit the Mediterranean Sea, according to a…